Myriad Neuroscience, a business unit of Myriad Genetics, specializes in pharmacogenomic testing. The GeneSight® Psychotropic test, developed in the Myriad Neuroscience clinical laboratory, analyzes clinically important genetic variations that may impact how a patient metabolizes and responds to certain psychiatric medications. The results of the test provides clinicians with information about which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on patient’s genetic makeup.
